Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
Oncotarget|November 5, 2017
Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cellsFloriana Morgillo, Carminia Maria Della Corte, Anna Diana, et al.
Scientific Reports|October 20, 2020
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patientsEmilio Francesco Giunta, Giusi Barra, Vincenzo De Falco, et al.
Cancer Investigation|May 21, 2010
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II studyMichele Orditura, Gennaro Galizia, Vincenzo Napolitano, et al.
Cancers|August 27, 2021
Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 AntibodiesGiuseppe Bellastella, Carla Carbone, Lorenzo Scappaticcio, et al.
ESMO Open|November 16, 2016
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysisMichele Orditura, Gennaro Galizia, Anna Diana, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 6, 2019
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer modelsValentina Belli, Nunzia Matrone, Stefania Napolitano, et al.
Oncotarget|May 4, 2018
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cellsVincenza Ciaramella, Carminia Maria Della Corte, Concetta Di Mauro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2013
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cellsTeresa Troiani, Erika Martinelli, Stefania Napolitano, et al.
Expert Opinion on Drug Safety|March 22, 2021
How can we manage the cardiac toxicity of immune checkpoint inhibitors?Remo Poto, Giancarlo Marone, Flora Pirozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2010
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cellsErika Martinelli, Teresa Troiani, Floriana Morgillo, et al.
Pageof 16